Karen Young Kreeger | Oct 15, 2000 | 5 min read
As more universities negotiate licensing agreements with biotech firms and big Pharma, unprecedented numbers of life scientists move between the Ivory Tower and industrial labs. Are the worlds of academia and industry colliding or meshing? How does the bottom line govern what science gets done? Although answers will vary from company to company, say life science researchers based in private sector research, there are more similarities than some might think. Lee Rubin, senior vice presiden